Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...
If your life story doesn’t include at least one chapter about the donuts at Sluys Poulsbo Bakery in Poulsbo, Washington, then ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results